During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub spoke to Srdan Verstovsek, MD Anderson Cancer Center, Houston, US. We asked, Does the bromodomain and extraterminal domain (BET) inhibitor CPI-0610 show synergy with ruxolitinib in myelofibrosis (MF)?